Regent Pacific Group Limited (RPGLF)
- Previous Close
0.0680 - Open
0.0680 - Bid --
- Ask --
- Day's Range
0.0680 - 0.0680 - 52 Week Range
0.0050 - 0.0840 - Volume
100 - Avg. Volume
1 - Market Cap (intraday)
15.531M - Beta (5Y Monthly) 0.91
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1100 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date Feb 8, 2013
- 1y Target Est
--
Regent Pacific Group Limited, an investment holding company, holds investments in the healthcare and life sciences sectors in Europe and Taiwan. The company operates in two segments, Biopharma and Corporate Investment. It engages in the research, development, manufacture, marketing, and sale of pharmaceutical products for the treatment and management of urological disorders; and development of artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological, and psychological levels. The company also invests in listed and unlisted corporate entities. In addition, it provides management services. The company was formerly known as Endurance RP Limited and changed its name to Regent Pacific Group Limited in July 2023. Regent Pacific Group Limited was incorporated in 1991 and is headquartered in Central, Hong Kong.
www.regentpac.com17
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Related News
Performance Overview: RPGLF
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RPGLF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RPGLF
Valuation Measures
Market Cap
12.40M
Enterprise Value
11.18M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
40.07
Price/Book (mrq)
--
Enterprise Value/Revenue
29.26
Enterprise Value/EBITDA
-1.44
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-119.94%
Return on Equity (ttm)
-4,789.48%
Revenue (ttm)
291k
Net Income Avi to Common (ttm)
-25.05M
Diluted EPS (ttm)
-0.1100
Balance Sheet and Cash Flow
Total Cash (mrq)
2.42M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--